Notice2026-09767
Oscar Bobo: Final Debarment Order
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 15, 2026
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Oscar Bobo for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Bobo engaged in a pattern of importing or offering for import misbranded drugs (i.e., in an amount, frequency, or dosage that is inconsistent with his personal or household use) that are not designated in an authorized electronic data interchange system as products regulated by FDA. Mr. Bobo was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 25, 2026 (30 days after receipt of the notice), Mr. Bobo had not responded. Mr. Bobo's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 94 (Friday, May 15, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 94 (Friday, May 15, 2026)]
[Notices]
[Pages 27962-27964]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-09767]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2025-N-0421]
Oscar Bobo: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C
Act) debarring Oscar Bobo for a period of 5 years from importing or
offering for import any drug into the United States. FDA bases this
order on a finding that Mr. Bobo engaged in a pattern of importing or
offering for import misbranded drugs (i.e., in an amount, frequency, or
dosage that is inconsistent with his personal or household use) that
are not designated in an authorized electronic data interchange system
as products regulated by FDA. Mr. Bobo was given notice of the proposed
debarment and was given an opportunity to request a hearing to show why
he should not be debarred. As of March 25, 2026 (30 days after receipt
of the notice), Mr. Bobo had not responded. Mr. Bobo's failure to
[[Page 27963]]
respond and request a hearing constitutes a waiver of his right to a
hearing concerning this matter.
DATES: This order is applicable May 15, 2026.
ADDRESSES: Any application by Mr. Bobo for termination of debarment
under section 306(d)(1) of the FD&C Act (21 U.S.C. 335a(d)(1)) may be
submitted at any time as follows:
Electronic Submissions
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. An application
submitted electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a> will be posted to the docket unchanged. Because
your application will be made public, you are solely responsible for
ensuring that your application does not include any confidential
information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number,
or confidential business information, such as a manufacturing process.
Please note that if you include your name, contact information, or
other information that identifies you in the body of your application,
that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit an application with confidential
information that you do not wish to be made available to the public,
submit the application as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
<bullet> Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For a written/paper application submitted to the Dockets
Management Staff, FDA will post your application, as well as any
attachments, except for information submitted, marked, and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All applications must include the Docket No. FDA-
2025-N-0421. Received applications will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit an application with
confidential information that you do not wish to be made publicly
available, submit your application only as a written/paper submission.
You should submit two copies total. One copy will include the
information you claim to be confidential with a heading or cover note
that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The
Agency will review this copy, including the claimed confidential
information, in its consideration of your application. The second copy,
which will have the claimed confidential information redacted/blacked
out, will be available for public viewing and posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. Submit both copies to the Dockets Management
Staff. If you do not wish your name and contact information to be made
publicly available, you can provide this information on the cover sheet
and not in the body of your comments and you must identify this
information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852 between 9 a.m. and 4 p.m., Monday through Friday, 240-402-
7500. Publicly available submissions may be seen in the docket.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of Field
Enforcement, Office of Field Regulatory Operations, Office of
Inspections and Investigations, Food and Drug Administration, at 240-
402-8743, or <a href="/cdn-cgi/l/email-protection#d7b3b2b5b6a5bab2b9a3a497b1b3b6f9bfbfa4f9b0b8a1"><span class="__cf_email__" data-cfemail="86e2e3e4e7f4ebe3e8f2f5c6e0e2e7a8eeeef5a8e1e9f0">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(D) of the FD&C Act permits debarment of an
individual from importing or offering for import any drug into the
United States if FDA finds, as required by section 306(b)(3)(D) of the
FD&C Act, that the individual has engaged in a pattern of importing or
offering for import (i.e., in an amount, frequency, or dosage that is
inconsistent with personal or household use) misbranded drugs that are
not designated in an authorized electronic data interchange system as
products regulated by FDA.
After an investigation, FDA discovered that Mr. Bobo had engaged in
numerous instances of importing or offering for import misbranded
drugs. Specifically, between April 5, 2019, and September 3, 2024, Mr.
Bobo imported or offered for import 8 parcels containing a total of 10
products (5,970 tablets) that contained tadalafil and sildenafil. FDA
determined that these drugs were misbranded because their labeling
lacked adequate directions for use, as required by section 502(f)(1) of
the FD&C Act (21 U.S.C. 352(f)(1)), and/or because the drugs were
prescription drugs and their labels failed to bear the symbol ``Rx
only'' as required by section 503(b)(4)(A) of the FD&C Act (21 U.S.C.
353(b)(4)(A)). All the parcels containing the misbranded drugs serving
as the basis for this action were intercepted by FDA at the John F.
Kennedy International Mail Facility and were addressed to Mr. Bobo at
an address connected to him.
As a result of this pattern of importing or offering for import
(i.e. in an amount, frequency, or dosage that is inconsistent with
personal or household use) misbranded drugs that are not designated in
an authorized electronic data interchange system as products regulated
by FDA, in accordance with section 306(b)(3)(D) of the FD&C Act, FDA
sent Mr. Bobo, by certified mail on February 17, 2026, a notice
proposing to debar him for a 5-year period from importing or offering
for import any drug into the United States. The attachment to that
notice contained a table listing all the parcels intercepted by FDA
that contained the misbranded drugs serving as a basis for this action.
Among other pieces of information, that table contained the submission
date of the entry, the product contained in the package, the quantity
of the product, and the product violation FDA found for each entry.
That attachment is posted to the docket and can be accessed by the
public at <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
In proposing a debarment period, FDA weighed the considerations set
forth in section 306(c)(3) of the FD&C Act that the Agency considered
applicable to Mr. Bobo's pattern of conduct and concluded that his
conduct warranted the imposition of a 5-year period of debarment. The
proposal informed Mr. Bobo of the proposed debarment and offered him an
opportunity to request a hearing, providing him 30 days from the date
of receipt of the letter in which to file the request, and advised him
that failure to request a hearing constituted a waiver of the
opportunity for a hearing and of any contentions concerning this
action. Mr. Bobo received the proposal and notice
[[Page 27964]]
of opportunity for a hearing on February 23, 2026. Mr. Bobo failed to
request a hearing within the timeframe prescribed by regulation and
has, therefore, waived his opportunity for a hearing and waived any
contentions concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Division of Field Enforcement Director, Office of
Inspections and Investigations, under section 306(b)(3)(D) of the FD&C
Act, under authority delegated to the Director, Division of
Enforcement, finds that Mr. Oscar Bobo has engaged in a pattern of
importing or offering for import (i.e., in an amount, frequency, or
dosage that is inconsistent with his personal or household use)
misbranded drugs that are not designated in an authorized electronic
data interchange system as products regulated by the FDA. FDA finds
that this pattern of conduct should be accorded a debarment period of 5
years as provided by section 306(c)(2)(A)(iii) of the FD&C Act.
As a result of the foregoing finding, Mr. Bobo is debarred for a
period of 5 years from importing or offering for import any drug into
the United States, effective (see DATES). Pursuant to section 301(cc)
of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering for
import into the United States of any drug by, with the assistance of,
or at the direction of Mr. Bobo during his period of debarment is a
prohibited act.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-09767 Filed 5-14-26; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 15, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.